Prevalence of BRCA in Patients with primary platinum sensitive recurrent ovarian cancer
- Conditions
- C56Malignant neoplasm of ovary
- Registration Number
- DRKS00006745
- Lead Sponsor
- AGO Research GmbH, AGO Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 530
Inclusion Criteria
1. Female ovarian cancer patients aged >= 18 years.
2. Women with first diagnosis of epithelial ovarian cancer OR women diagnosed with platinum-sensitive recurrent ovarian cancer (i.e., women who have received an initial course of platinum-based chemotherapy and with no evidence of disease progression for at least 6 months after the last administration of a platinum-based regimen for initial treatment).
3. Multiple platinum based prior therapies are allowed.
Exclusion Criteria
1. Non-epithelial ovarian malignancy.
2. Platinum resistant or refractory disease.
3. Paraffin embedded tumor samples not available.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evidence of germline alterations in BRCA1/2 and other ovarian cancer predisposing genes
- Secondary Outcome Measures
Name Time Method • Immunohistochemistry and DNA extraction from tumor samples • Evidence of somatic alterations in BRCA1/2 and other ovarian cancer predisposing genes • Evidence for a BRCAness tumor phenotype in ovarian cancer • Differences of tumor samples from primary and relapsed disease • Evaluation of patient perspectives and satisfaction regarding testing and counseling (survey)<br>